Section Sub-head
Header
Sub-head
Header
Sub-head
-
Latest Real-World Clinical Data Demonstrate a 19.6 mmHg Reduction in Blood Pressure at 6 Months with Recor Medical’s Paradise Ultrasound Renal Denervation System
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced results from two clinical studies presented at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference this week: data from the Global Paradise System (GPS) Registry demonstrated a 19.6 mmHg reduction in office systolic blood pressure at six months with…
-
CMS Issues National Coverage Determination for Recor Medical’s Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced that the Centers for Medicare and Medicaid Services (CMS) has issued its National Coverage Determination (NCD) for Renal Denervation (RDN), including Recor’s Paradise® Ultrasound Renal Denervation (uRDN) system, a device-based therapy for patients with uncontrolled hypertension whose blood…
-
Recor Medical Announces Paradise Ultrasound Renal Denervation System Receives Manufacturing and Marketing Approval in Japan for the Treatment of Resistant Hypertension
Recor Medical, Inc. (“Recor”), a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today that the Paradise™ Ultrasound Renal Denervation (uRDN) system has received approval for manufacturing and marketing in Japan for the treatment of resistant hypertension. This marks the first approval in the country for a medical device indicated for the disease.
-
Recor Medical Responds to the American Heart Association (AHA) and American College of Cardiology’s (ACC) Updated Guidelines on Renal Denervation for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), appreciate the American Heart Association (AHA) and American College of Cardiology (ACC) for highlighting renal denervation (RDN) as a therapeutic option for resistant or uncontrolled hypertension in the joint 2025 Guidelines. The AHA/ACC Guidelines integrate the latest scientific data,…
-
Recor Medical Supports Proposed CMS National Coverage Determination of Renal Denervation for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”), today announced their support for the Centers for Medicare and Medicaid Services’ (CMS) proposed National Coverage Determination (NCD) for Renal Denervation (RDN), a device-based therapy for patients with uncontrolled hypertension—individuals whose blood pressure cannot be properly managed with lifestyle…
-
Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension
May 17, 2025, is World Hypertension Day, a day dedicated to raising awareness about high blood pressure, also known as the “silent killer” because many people do not know they have it and, over time, it can lead to serious health issues. The theme of World Hypertension Day, “Measure Your Blood Pressure Accurately, Control It,…